Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Going into Tax Reform Debate for FY2021
November 20, 2020
- Fully Implement Off-Year Drug Re-Pricing: LDP Fiscal Consolidation HQ
November 20, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Prevention on Dec. 2
November 19, 2020
- MHLW Mulls Health Follow-Up on 10,000-Plus COVID-19 Vaccine Recipients
November 19, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
- Chuikyo Healthcare, Payer Reps Still Divided Over Off-Year Re-Pricing Debate
November 19, 2020
- Japan Should Consider Mass Vaccinations for COVID-19: JMA Official
November 18, 2020
- MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
November 18, 2020
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
- With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
- “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
November 16, 2020
- PMDA Reviewing New Safety Risks for Soliris, Venclexta/Noxafil
November 16, 2020
- MHLW to Continue Follow-Up on Veklury’s Safety/Efficacy Info: Official
November 16, 2020
- MHLW Weighs COVID-19 Vaccinations outside Medical Institutions
November 16, 2020
- COVID-19 Vaccinations for HCPs Not Mandatory: Health Minister
November 16, 2020
- HPV Vaccine Is “Social Justice”: LDP Lawmaker
November 13, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…